BullFrog AI Holdings, Inc. (Nasdaq: BFRG) is a digital biopharmaceutical company that uses causal artificial intelligence and machine learning to analyze complex biomedical data for drug target discovery and clinical trial optimization. The company operates through three proprietary modules: bfPREP for data harmonization, bfLEAP for causal analytics, and bfARENAS for strategic decision support .
At-a-Glance: Key Takeaways
- BullFrog AI is a commercial-stage AI drug discovery company headquartered in Gaithersburg, Maryland, founded in 2017 and listed on Nasdaq under the ticker BFRG .
- The company secured a commercial agreement with a top 5 global pharmaceutical company in March 2026 to identify novel drug targets for major depressive disorder .
- Its technology heritage traces to the Johns Hopkins University Applied Physics Laboratory, with exclusive worldwide licenses for multiple patented AI methods .
- BullFrog AI regained Nasdaq compliance in April 2026 after falling below the minimum stockholders’ equity requirement, but remains subject to a mandatory panel monitor for one year .
- The company reported a cash runway into late 2027 following financing activities completed in March and April 2026 .
- **Market capitalization stood at approximately $10.5 million** as of October 2026, with shares trading below $1 .
What Is BullFrog AI?
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company that applies artificial intelligence and machine learning to pharmaceutical research and development . Unlike AI companies building general-purpose models, BullFrog AI operates in a narrow vertical: using causal AI to analyze complex biological data for drug target discovery, patient stratification, and clinical trial optimization.
The company was founded in 2017 and is headquartered in Gaithersburg, Maryland . It went public through a Nasdaq listing and trades under the ticker BFRG, with warrants under BFRGW .
BullFrog AI’s core thesis is that pharmaceutical R&D suffers from a data problem, not just a science problem. Biomedical datasets are fragmented, noisy, and stored across incompatible systems. The company’s platform aims to harmonize that data, apply causal inference to uncover biological relationships, and translate findings into defensible strategic decisions .
How BullFrog AI Works
BullFrog AI’s technology stack consists of three complementary modules. Each can be deployed independently, but the company positions them as an end-to-end workflow for pharmaceutical partners .
bfPREP: Biology-Aware Data Harmonization
The first module addresses a fundamental bottleneck in AI-driven drug discovery: data readiness. Pharmaceutical companies possess vast datasets, but they are often unstructured, inconsistently coded, and scattered across legacy systems .
bfPREP automates data cleansing, normalization, and transformation. According to company claims, it can reduce data preparation timelines from months to days. This module was originally developed to support BullFrog AI’s collaboration with Eleison Pharmaceuticals and now serves as an entry point for deeper analytical engagements .
bfLEAP: Causal AI Analytics
bfLEAP is the analytical core. It applies causal network inference and machine learning to identify drug targets, patient subgroups, and disease drivers from multimodal datasets . Unlike correlation-based machine learning models that identify statistical associations, causal AI attempts to model the underlying biological mechanisms.
This distinction matters in pharmaceutical R&D. A correlation-based model might flag a gene as associated with a disease without establishing whether the gene drives the disease or merely accompanies it. Causal inference aims to identify targets that, when modulated, would actually change disease outcomes .
BullFrog AI claims its platform generates “explainable insights built to withstand scientific and regulatory scrutiny,” with every output traceable and every analytical decision logged .
bfARENAS: Strategic Decision Support
The newest module, launched in March 2026, translates biological insights into portfolio and clinical trial design decisions .
Traditional portfolio tools collapse complex judgments into single scores. bfARENAS takes a different approach: it evaluates options through head-to-head comparison across multiple explicit scenarios, such as capital-constrained, platform-building, US-first, or global strategies. The goal is to identify options that perform well across multiple futures, not just under a single assumed scenario .
Commercial Progress and Partnerships
The Top 5 Pharmaceutical Agreement
BullFrog AI’s most significant commercial milestone came in March 2026. The company announced a commercial agreement with a top 5 global pharmaceutical company by 2025 revenue to apply bfLEAP to identify and prioritize novel drug targets in major depressive disorder (MDD) .
The MDD market was valued at more than $8 billion in 2025 and is projected to exceed $11 billion by 2032. The agreement includes milestone payments tied to deliverables and provides the partner with an option to secure exclusive rights to a final selected target candidate .
By October 2026, BullFrog AI announced it had achieved key project milestones, successfully identifying and prioritizing novel therapeutic targets using proprietary neuropsychiatric multi-omic datasets. CEO Vin Singh described the project as “crucial commercial scale validation of our technology” .
Eleison Pharmaceuticals Collaboration
BullFrog AI’s collaboration with Eleison Pharmaceuticals represents its first substantive real-world deployment in late-stage oncology . The companies applied bfLEAP and bfPREP to analyze complex clinical trial data for patient stratification and trial optimization in a pivotal Phase 3 setting.
An abstract co-authored by BullFrog AI, Eleison, and researchers from Moffitt Cancer Center was accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium. The study explored data-driven precision-oncology approaches to identify patient subtypes with potential enhanced response to glufosfamide in pancreatic cancer .
Sygnature Discovery Sales Partnership
In 2025, BullFrog AI entered a commercial collaboration with Sygnature Discovery, a global contract research organization. Sygnature’s business development team now introduces BullFrog Data Networks to its biopharma client base, expanding commercial reach with limited incremental investment from BullFrog AI .
Technology Heritage and Intellectual Property
BullFrog AI’s technology derives from research conducted at the Johns Hopkins University Applied Physics Laboratory. The company holds exclusive worldwide licenses for multiple patented methods, including:
- U.S. Patent 10,146,801: Apparatus and Method for Distributed Graph Processing
- U.S. Patent 10,936,965: Method and Apparatus for Analysis and Classification of High Dimensional Data Sets
- U.S. Patent 10,839,256: Generalized Low Entropy Mixture Model
These patents, assigned to Johns Hopkins University, are exclusively licensed to BullFrog AI for therapeutics development and analytical services. The license agreement requires BullFrog AI to meet development milestones and pay royalties on net sales, with minimum annual payments escalating to $300,000 .
The company also collaborates with the Lieber Institute for Brain Development, accessing a proprietary dataset of more than 2,800 human brain samples for neuropsychiatric research .
Financial Position and Stock Performance
Market Capitalization and Share Price
As of October 2026, BullFrog AI’s market capitalization stood at approximately $10.5 million. The stock traded around $0.57 per share, well below its 52-week high of $1.96 reached in March 2026 .
The company reported revenue of $298,800 on a trailing twelve-month basis, with a net margin of negative 2,006% . Enterprise value was approximately $3.72 million, reflecting the company’s cash position against its market cap .
Cash Runway and Financing
BullFrog AI has taken deliberate steps to fortify its financial position. Through sales under its at-the-market and equity-line-of-credit facilities completed in late March 2026, the company reported stockholders’ equity in excess of $2.5 million .
Management stated that based on current cash burn rate, the proceeds should provide capital sufficient to support operations into late 2027. The company maintains a lean cost structure with an annual burn of approximately $6.2 million, which management believes creates operating leverage as commercial revenue scales .
Nasdaq Compliance Status
BullFrog AI faced a significant regulatory challenge in 2025 and 2026. On August 21, 2025, the company received a letter from Nasdaq stating it was no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million .
After submitting a compliance plan and receiving an extension, Nasdaq determined in February 2026 that the company had not met the extension terms. BullFrog AI requested a hearing before a Nasdaq Hearings Panel, which automatically stayed delisting action .
Following the hearing on March 31, 2026, BullFrog AI completed stock sales that raised aggregate net proceeds of at least $3.45 million. On April 21, 2026, Nasdaq notified the company that it had regained compliance with the Stockholders’ Equity Rule. The company remains subject to a mandatory panel monitor for one year .
Privacy and Security Considerations
BullFrog AI’s platform handles sensitive pharmaceutical and biomedical data, including clinical trial data and proprietary research. The company states that its platform supports native deployment across all major cloud environments and is “built for scalability, security, and flexibility” .
The company’s architecture is designed to meet enterprise customers where their data resides, supporting deployment within existing infrastructure and workflows. This approach addresses a common concern among pharmaceutical companies about data governance and control .
Important caveat: Available public documentation does not reference specific security certifications such as SOC 2, ISO 27001, or Zero Data Retention guarantees. Enterprise buyers should conduct their own due diligence on data handling practices.
Common Mistakes and Cautions
Confusing BullFrog AI with consumer AI products. BullFrog AI is not a chatbot or general-purpose AI tool. It is a specialized platform for pharmaceutical R&D, sold through enterprise agreements to biopharma companies .
Overlooking the going concern risk. BullFrog AI’s SEC filings explicitly state that the company’s ability to continue as a going concern depends on securing additional capital or revenue. While management projects runway into late 2027, this forecast is subject to significant assumptions and uncertainties .
Assuming commercial traction equals profitability. The top 5 pharma agreement is a validation milestone, but BullFrog AI remains pre-profitability with minimal revenue. Converting pilots into larger, multi-year strategic partnerships is a stated priority, not a completed achievement .
Ignoring dilution risk. The company’s SEC filings note that issuance of additional equity securities “may be significantly dilutive to the Company’s current shareholders” .
FAQs
What does BullFrog AI do?
BullFrog AI is a digital biopharmaceutical company that applies causal AI and machine learning to drug discovery and development. Its platform helps pharmaceutical companies identify drug targets, stratify patients, and optimize clinical trial design. The company operates through three modules: bfPREP, bfLEAP, and bfARENAS .
Is BullFrog AI a good investment?
This is not a recommendation. BullFrog AI is a micro-cap stock with significant risks including going concern uncertainty, minimal revenue, and dilution risk. The company has commercial validation through a top 5 pharma agreement, but has not yet demonstrated sustained profitability. Investors should review SEC filings and consult financial advisors.
What is BullFrog AI’s stock ticker?
BullFrog AI trades on Nasdaq under the ticker BFRG. Warrants trade under BFRGW .
What is bfLEAP?
bfLEAP is BullFrog AI’s proprietary causal AI analytics platform. It applies causal network inference and machine learning to identify drug targets, patient subgroups, and disease drivers from complex biomedical datasets .
Has BullFrog AI regained Nasdaq compliance?
Yes. BullFrog AI regained compliance with Nasdaq’s minimum stockholders’ equity requirement on April 21, 2026, following financing activities that raised at least $3.45 million in net proceeds. The company remains subject to a mandatory panel monitor for one year .
Conclusion
BullFrog AI is a specialized AI company operating at the intersection of causal inference and pharmaceutical R&D. Its technology heritage from Johns Hopkins University, exclusive patent licenses, and commercial agreement with a top 5 global pharmaceutical company provide credible validation of its platform.
What matters most is execution. The company has moved from research to commercial stage, but remains pre-profitability with a $10.5 million market cap and going concern risk. Converting the initial pharma agreement into larger, multi-year partnerships is the critical milestone ahead.
BullFrog AI may suit enterprise pharmaceutical and biotechnology organizations seeking AI-driven drug target discovery and clinical trial optimization. It may not suit investors seeking near-term profitability or general users looking for consumer AI tools.
Before investing, evaluate the company’s cash runway, dilution history, and progress toward converting pilots into recurring revenue. Read the SEC filings carefully. And remember that commercial validation, while meaningful, is not the same as financial sustainability.
